UBS Group’s Apollo Endosurgery, Inc. APEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-223
Closed -$2.21K 10401
2023
Q1
$2.21K Sell
223
-35,105
-99% -$348K ﹤0.01% 8551
2022
Q4
$352K Buy
35,328
+31,773
+894% +$237K ﹤0.01% 4991
2022
Q3
$20K Buy
3,555
+526
+17% +$2.92K ﹤0.01% 7438
2022
Q2
$11K Buy
3,029
+1,378
+83% +$6.51K ﹤0.01% 7906
2022
Q1
$10K Sell
1,651
-137
-8% -$835 ﹤0.01% 8484
2021
Q4
$15K Buy
1,788
+1,392
+352% +$12.2K ﹤0.01% 8288
2021
Q3
$3K Sell
396
-3,332
-89% -$28.6K ﹤0.01% 8887
2021
Q2
$30K Buy
3,728
+2,432
+188% +$16.7K ﹤0.01% 6953
2021
Q1
$7K Sell
1,296
-2,670
-67% -$13.2K ﹤0.01% 8181
2020
Q4
$13K Buy
3,966
+1,517
+62% +$4K ﹤0.01% 7307
2020
Q3
$4K Buy
2,449
+1,454
+146% +$2.19K ﹤0.01% 7469
2020
Q2
$2K Sell
995
-4,160
-81% -$8.26K ﹤0.01% 7692
2020
Q1
$10K Buy
5,155
+4,611
+848% +$12.1K ﹤0.01% 6951
2019
Q4
$2K Sell
544
-600
-52% -$1.74K ﹤0.01% 7881
2019
Q3
$4K Sell
1,144
-37
-3% -$117 ﹤0.01% 7583
2019
Q2
$4K Sell
1,181
-184
-13% -$654 ﹤0.01% 7478
2019
Q1
$5K Sell
1,365
-3,220
-70% -$11.3K ﹤0.01% 7203
2018
Q4
$16K Sell
4,585
-2,469
-35% -$12.2K ﹤0.01% 6964
2018
Q3
$51K Buy
7,054
+3,398
+93% +$26.4K ﹤0.01% 6154
2018
Q2
$26K Buy
3,656
+1,982
+118% +$12.3K ﹤0.01% 6516
2018
Q1
$10K Buy
+1,674
New +$10.5K ﹤0.01% 6894
2017
Q2
Sell
-1,014
Closed -$13K 8095
2017
Q1
$13K Sell
1,014
-2,490
-71% -$31.7K ﹤0.01% 6472
2016
Q4
$43K Buy
+3,504
New +$53.4K ﹤0.01% 5948
2016
Q3
Sell
-531
Closed -$6K 8023
2016
Q2
$6K Buy
+531
New +$7.98K ﹤0.01% 7063
2015
Q1
Sell
-7
Closed -$2K 9555
2014
Q4
$2K Buy
+7
New +$1.56K ﹤0.01% 9441

UBS Group's APEN Position: Q2 2023 in Review

UBS Group sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 223 shares — an estimated $2.21K sold.

UBS Group first reported a position in APEN in Q4 2014 and held it in 25 quarters. The position peaked at $352K in Q4 2022. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

  • UBS Group reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 223 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $2.21K.
  • UBS Group first reported a position in Apollo Endosurgery, Inc. in Q4 2014 and held it in 25 quarters.
  • UBS Group's Apollo Endosurgery, Inc. position peaked at $352K in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.